×

The Female Health Company to Present at LD MICRO “Main Event” Investor Conference on Thursday, December 3, 2015

CHICAGO, Nov. 17, 2015 (GLOBE NEWSWIRE) -- The Female Health Company (FHC) (NASDAQ:FHCO), manufacturer of the world’s leading female condom, the FC2, today announced that it will be presenting at the LD MICRO “Main Event” Investor Conference on Thursday, December 3, 2015. The conference, which will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California, will feature 200 small/micro-cap companies and is expected to host more than 1,000 portfolio managers, research analysts, and other investors.

The presentation by O. B. Parrish, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 9:30 a.m. Pacific Standard Time (PST) on Thursday, December 3, 2015. Management will be available during the day for one-on-one meetings. To schedule a meeting, please contact your LD MICRO representative or Eric Lahiji at Eric@ldmicro.com.

About LD MICRO

LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD MICRO “Main Event” Investor Conference for investors in December of each year.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.

Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123

Source:The Female Health Company